ARTICLE | Clinical News
Lilly discontinues enzastaurin after Phase III miss
May 11, 2013 12:36 AM UTC
Eli Lilly and Co. (NYSE:LLY) discontinued development of enzastaurin (LY31765) after top-line data showed daily enzastaurin missed the primary endpoint of improving disease-free survival (DFS) vs. pla...